Investment Rating - The report maintains an "Outperform" rating for Li Ning, with a target price of HKD 21.00, indicating a potential upside of 12.1% from the current price of HKD 18.77 [2][15]. Core Insights - Li Ning's operating profit for 1H25 exceeded market expectations, with revenue reaching RMB 14.82 billion, a year-on-year increase of 3.3%. The growth was driven by the wholesale and e-commerce channels, while the self-operated channel saw a decline due to store closures [3][12]. - The company continues to implement a single-brand, multi-category strategy, focusing on professional product expansion, which has led to revenue growth in footwear and accessories [4][13]. - Olympic marketing is a central theme in Li Ning's mid-term strategy, with increased marketing expenses expected in the second half of the year [6][14]. Financial Performance Summary - Revenue projections for 2025-2027 are RMB 29.13 billion, RMB 30.64 billion, and RMB 32.30 billion, reflecting year-on-year growth rates of 1.6%, 5.2%, and 5.4% respectively [7][16]. - Net profit attributable to shareholders is forecasted to be RMB 2.49 billion, RMB 2.84 billion, and RMB 3.17 billion for the same period, with a notable decline of 17.3% in 2025, followed by growth in subsequent years [7][16]. - The gross margin for 1H25 was reported at 50%, a slight decrease of 0.4 percentage points year-on-year, influenced by deeper discounting and changes in channel contributions [3][12]. Category and Channel Adjustments - The company has concluded its category and channel adjustments, with a focus on enhancing brand equity and consumer engagement through Olympic marketing initiatives [15][16]. - Li Ning's footwear and apparel categories have shown mixed performance, with footwear revenue growing by 5% while apparel declined by 3% [4][13]. - The basketball category experienced a significant decline of 20% in revenue, attributed to proactive order control to maintain brand equity [4][13].

Investment Rating - The report maintains a "Recommended" rating for China Resources Land (01109.HK) with a target price of HKD 38.8 [2][8] Core Insights - In the first half of 2025, the company achieved revenue of HKD 949.2 billion, a year-on-year increase of 19.9%, and a net profit attributable to shareholders of HKD 118.8 billion, up 16.2% year-on-year [2][8] - The core net profit contribution from recurring business is 60.2%, with a gross margin recovery in the development and sales business [8] - The company actively acquired land, maintaining a strong investment intensity, ranking among the top three in the industry [8] Financial Performance Summary - Total revenue for 2024 is projected at HKD 278.8 billion, with a year-on-year growth rate of 10.6%. However, a slight decline is expected in 2025 with a revenue forecast of HKD 277.8 billion, reflecting a decrease of 0.4% [4] - The net profit attributable to shareholders is expected to decrease to HKD 24.4 billion in 2025, down 4.7% from 2024 [4] - Earnings per share (EPS) for 2025 is projected at HKD 3.42, with a price-to-earnings (P/E) ratio of 8.4 [4][8] Business Segment Analysis - The development and sales business accounted for 78% of total revenue, with a settlement income of HKD 743.6 billion, up 25.8% year-on-year, and a gross margin of 15.6%, an increase of 3.2 percentage points [8] - The recurring business generated revenue of HKD 205.6 billion, a 2.5% increase year-on-year, contributing 60.2% to the core net profit [8] - The shopping center segment showed stable growth, with retail sales reaching HKD 1,101.5 billion, a 20.2% increase year-on-year, and an operating profit margin of 65.9% [8] Investment Strategy - The company focuses on high-energy cities for land acquisition, with a projected increase in shopping center rental income to HKD 270 billion by 2028 [8] - The report adjusts the EPS forecast for 2025-2027 to HKD 3.42, HKD 3.72, and HKD 3.89 respectively, reflecting a cautious outlook on commercial operations [8]

Investment Rating - The investment rating for the company is "Outperform" (maintained) [1] Core Views - The company has narrowed its losses in H1 2025, with significant growth potential driven by overseas expansion and the robotics sector [5] - The sales of advanced driver-assistance products and solutions have increased, benefiting from the production and delivery of multiple models in the passenger vehicle sector [4][5] - The company is making substantial investments in hardware and human resources to expand downstream application scenarios, leading to revised revenue and net profit forecasts for 2025-2027 [4] Financial Summary and Valuation Indicators - For H1 2025, the company achieved revenue of 252 million, a year-on-year increase of 40.4%, but below Bloomberg consensus expectations of 420 million [5] - The revenue from advanced driver-assistance products and solutions was 237 million, up 41.6% year-on-year, driven by increased sales of driver-assistance chips and solutions [5] - The company expects revenues for 2025, 2026, and 2027 to be 765 million, 1.293 billion, and 2.027 billion respectively, with year-on-year growth rates of 61.3%, 69.0%, and 56.8% [7] - The adjusted net profit for 2025 is projected at -1.421 billion, with further losses expected in 2026 and 2027 [4][7] - The current stock price corresponds to price-to-sales ratios of 14.0, 8.3, and 5.3 for 2025, 2026, and 2027 respectively [4][7]

Investment Rating - The report maintains a "Buy" rating for Jiangsu Ninghu Expressway [2][7][17] Core Views - The company's performance slightly underperformed expectations due to changes in the dividend cycle of Jiangsu Bank, with a reported revenue of RMB 9.406 billion, a year-on-year decrease of 5.6% [7] - The toll revenue for H1 2025 showed a stable increase, amounting to approximately RMB 4.6 billion, reflecting a year-on-year growth of about 1.65% [7] - The ongoing expansion projects are expected to significantly improve regional traffic flow, with the completion of key infrastructure projects by the end of 2025 and mid-2026 [7] Financial Data and Profit Forecast - Revenue projections for the company are as follows: - 2023: RMB 15.192 billion - 2024: RMB 23.198 billion - 2025E: RMB 23.935 billion - 2026E: RMB 24.730 billion - 2027E: RMB 25.436 billion - Year-on-year growth rates for revenue are projected at 15% for 2023, 53% for 2024, and 3.2% for 2025E [6][8] - Net profit attributable to shareholders is forecasted as follows: - 2023: RMB 4.413 billion - 2024: RMB 4.947 billion - 2025E: RMB 5.447 billion - 2026E: RMB 5.790 billion - 2027E: RMB 6.049 billion - The projected PE ratios are 10 for 2023, 9 for 2024, and 8 for 2025E [6][8]

Investment Rating - The investment rating for the company is "Buy" and is maintained [5]. Core Insights - The company reported a significant increase in revenue and net profit for the first half of 2025, achieving revenue of 5.42 billion and a net profit of 750 million, representing year-on-year growth of 46% and 93% respectively [2][4]. - The company experienced substantial growth in overseas markets, with overall sales volume increasing by 23.6% to 10.82 million tons, while aggregate sales volume rose by 39.4% to 2.23 million tons [4]. - The company is actively pursuing capacity integration, including the acquisition of 1.2 million tons of cement capacity in Congo and the sale of its Xinjiang operations, totaling 3.5 million tons of cement capacity [4]. - The company anticipates continued expansion in overseas markets, particularly in Africa, which presents significant growth potential and higher profitability compared to domestic markets [4]. Summary by Sections Financial Performance - For the first half of 2025, the company achieved revenue of 5.42 billion, with 3.07 billion from the Chinese market and 2.35 billion from overseas markets. The overall gross profit was 1.63 billion, with domestic gross profit at 680 million and overseas gross profit at 950 million [4]. Sales Volume Analysis - Domestic sales volume decreased by 8.3% to 6.65 million tons, while the average selling price increased by 4.1% to 280 per ton, resulting in a gross profit of 64 per ton. In contrast, overseas sales volume surged by 178% to 4.17 million tons, with an average selling price of 486 per ton, leading to a gross profit of 181 per ton [4]. Capacity Expansion - The company has a total domestic cement production capacity of 28.5 million tons across 17 production lines, with significant capacities in Shaanxi, Guizhou, and Sichuan. The overseas production capacity stands at 13.6 million tons across 7 production lines, with ongoing projects expected to increase this capacity to 14.8 million tons [4]. Future Outlook - The company projects earnings of 1.4 billion and 1.9 billion for 2025 and 2026, respectively, corresponding to price-to-earnings ratios of 9 and 7 times, indicating a positive outlook for future performance [4].

Investment Ratings - China Merchants Bank: BUY with a target price of HK$54.42 [5][6] - Agricultural Bank of China: BUY with a target price of HK$6.09 [7][8] - Postal Savings Bank of China: BUY with a target price of HK$6.35 [10][12] - Industrial and Commercial Bank of China: BUY with a target price of HK$7.15 [13][14] - China Construction Bank: BUY with a target price of HK$8.95 [15][16] - China Everbright Bank: BUY with a target price of HK$3.98 [18][19] - 3SBio Inc: BUY with a target price of HK$38.20 [20][21] - Longfor Group: HOLD with a target price of HK$9.52 [23][24][25] Core Insights - China Merchants Bank's attributable net profit increased by 2.7% YoY in 2Q25, recovering from a 2.1% decline in 1Q25, with outstanding asset quality but a drop in NIM [5][6] - Agricultural Bank of China's attributable net profit rose by 3.2% YoY in 2Q25, maintaining stable asset quality despite a slight decline in NIM [7][8] - Postal Savings Bank of China's net profit increased by 4.8% YoY in 2Q25, with strong asset quality and an attractive valuation [10][12] - Industrial and Commercial Bank of China's net profit grew by 1.4% YoY in 2Q25, showing improvement in asset quality and attractive valuation [13][14] - China Construction Bank's net profit increased by 1.6% YoY in 2Q25, with a decline in net interest income but solid asset quality [15][16] - China Everbright Bank's net profit rose by 0.8% YoY in 2Q25, with expectations of maintaining solid asset quality despite a declining NIM [18][19] - 3SBio Inc's revenue declined by 0.8% YoY in 1H25, but adjusted net profits increased by 2.1% YoY, with new product launches driving sales [20][21] - Longfor Group's revenue grew by 25.4% YoY in 1H25, but gross margin narrowed significantly, leading to a substantial decline in core net profit [23][24][25] Summary by Company China Merchants Bank - Attributable net profit increased 2.7% YoY in 2Q25 after a decline in 1Q25 [5][6] - Asset quality remains outstanding, but NIM dropped in 1H25 [5][6] - Target price revised to HK$54.42, maintaining BUY rating [5][6] Agricultural Bank of China - Attributable net profit increased 3.2% YoY in 2Q25 [7][8] - NIM was 1.32% in 1H25, down from 2024 [7][8] - Target price raised to HK$6.09, maintaining BUY rating [7][8] Postal Savings Bank of China - Attributable net profit increased 4.8% YoY in 2Q25 [10][12] - NIM reached 1.70% at end-June 2025 [10][12] - Target price revised to HK$6.35, maintaining BUY rating [10][12] Industrial and Commercial Bank of China - Attributable net profit increased 1.4% YoY in 2Q25 [13][14] - NIM reached 1.30% in 1H25 [13][14] - Target price raised to HK$7.15, maintaining BUY rating [13][14] China Construction Bank - Attributable net profit increased 1.6% YoY in 2Q25 [15][16] - Net interest income dropped 1.1% YoY in 2Q25 [15][16] - Target price raised to HK$8.95, maintaining BUY rating [15][16] China Everbright Bank - Attributable net profit increased 0.8% YoY in 2Q25 [18][19] - NIM expected to decline in 2025 [18][19] - Target price raised to HK$3.98, maintaining BUY rating [18][19] 3SBio Inc - Revenue declined by 0.8% YoY in 1H25 [20][21] - Adjusted net profits increased by 2.1% YoY [20][21] - Target price lifted to HK$38.20, reiterating BUY rating [20][21] Longfor Group - Revenue grew by 25.4% YoY in 1H25 [23][24][25] - Gross margin narrowed significantly, leading to a decline in core net profit [23][24][25] - Target price cut to HK$9.52, maintaining HOLD rating [23][24][25]

Investment Rating - The report maintains a "Buy" rating for Ctrip Group-S (09961.HK) with a target price of 606.90 HKD, reflecting a potential upside from the current closing price of 576.00 HKD [5][3][20]. Core Insights - Ctrip's Q2 2025 performance is strong, with net operating revenue reaching 14.8 billion RMB, a year-on-year increase of 16%, and net profit of 4.9 billion RMB, up 26% year-on-year. The growth is driven by robust travel demand, particularly during holiday periods [1][9]. - The international business segment shows significant growth, with total bookings on the international OTA platform increasing by over 60% year-on-year, driven by the Asia-Pacific region and mobile bookings, which now account for 70% of total bookings [1][17]. - The report highlights the increasing participation and purchasing power of the silver-haired demographic through the "Old Friends Club," which saw user numbers and GMV grow over 100% since the end of 2024 [2][19]. Summary by Sections International Business Growth - Ctrip's international OTA platform has shown strong growth, with inbound travel bookings more than doubling year-on-year, primarily driven by demand from South Korea and Southeast Asia [1][17]. - Domestic travelers' enthusiasm for outbound travel continues to recover, with bookings for hotels and flights exceeding 120% of the same period in 2019 [1][17]. Financial Forecast and Investment Recommendations - The report projects revenues of 61.82 billion RMB for 2025, with a year-on-year growth rate of 16.0%, and net profit of 17.71 billion RMB, reflecting a growth rate of 3.7% [3][20]. - Ctrip's domestic business remains strong, while international operations are expected to contribute additional growth, making it a valuable long-term investment [3][20]. - The expected PE ratios for 2025-2027 are 21.4X, 18.6X, and 15.9X, respectively, indicating a favorable valuation outlook [3][20].

Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [1][9]. Core Insights - The company has shown impressive sales performance and steady progress in innovation and research, with a significant revenue increase of 812% year-on-year for the first half of 2025, amounting to 499 million yuan, while losses narrowed by 77% to 78.79 million yuan [4][5]. - The core pipeline product, Supachibai monoclonal antibody (brand name: Kangyueda), has received approval for three indications: moderate to severe atopic dermatitis (AD), chronic rhinosinusitis with nasal polyps (CRSwNP), and seasonal allergic rhinitis (SAR), contributing approximately 169 million yuan to revenue in the first half of 2025 [5][6]. - The company is positioned as a leader in domestic autoimmune innovative drugs, with a robust pipeline and multiple products nearing commercialization, which is expected to enhance its long-term growth prospects [9]. Company Overview - The latest closing price is 69.15 HKD, with a total market capitalization of 20.7 billion HKD. The company has a debt-to-asset ratio of 31% and a price-to-earnings ratio of -73.2 [3][4]. - The largest shareholder is Moonshot Holdings Limited [3]. Financial Projections - Revenue projections for 2025-2027 are 880 million, 1.5 billion, and 2.2 billion yuan, respectively, with year-on-year growth rates of 106%, 70%, and 49% [9][11]. - The company is expected to achieve a net profit of 0.1 billion yuan by 2027, transitioning from losses in the earlier years [9][11].

Investment Rating - The investment rating for the company is "Outperform the Market" [6] Core Views - The report emphasizes that Anta Sports has a well-structured brand matrix that aligns with industry trends, enabling gradual growth [2] - The company is positioned to benefit from the diversification of the Chinese sports market and the potential for global expansion, which could lead to significant long-term growth opportunities [4][9] Industry Trends - The Chinese sports market is diversifying, with the sports footwear and apparel market reaching approximately 400 billion yuan, and a pre-pandemic compound annual growth rate (CAGR) of 17% [1][18] - The penetration rate of the sports market is expected to rise from 7.3% in 2010 to 15.3% by 2024, indicating a strong growth trajectory [1][18] - The industry has experienced three growth cycles, with the current phase focusing on professional and outdoor sports [1][21] Company Overview - Anta Sports is projected to achieve revenues of 70.8 billion yuan in 2024, with a gross margin of 62% [2] - The company operates a multi-brand strategy with three main brand groups: professional, outdoor, and fashion, which are all growing in synergy [2] - Recent acquisitions, such as MAIA ACTIVE and Wolf Claw, have expanded the brand matrix and enhanced global competitiveness [2] Competitive Strengths - Anta Sports is capitalizing on the trend of integrating sports with leisure and social activities, with each brand catering to specific consumer needs [3] - The main brand focuses on affordable professional sports products, while high-end brands like FILA leverage design and celebrity endorsements to capture market share [3] Growth Potential - The brand matrix is expected to stimulate incremental demand, with global operations likely to yield significant growth opportunities [4] - The report forecasts that the company's net profit will grow from over 1 billion yuan this year to more than 2 billion yuan in three years, driven by strong brand performance [5][9] Financial Forecast - The company is expected to achieve a net profit of 13.48 billion yuan in 2025, with a comparable profit growth of 13.0% [9][10] - Revenue projections for the next three years indicate a steady increase, with expected revenues of 80.83 billion yuan in 2025 [10]

Investment Rating - The report maintains an "Outperform" rating for Sino Biopharmaceutical with a target price of HKD 10.87, reflecting a positive outlook on the company's performance [2][7]. Core Insights - Sino Biopharmaceutical achieved revenue of CNY 17.6 billion in 1H25, representing an 11% year-on-year increase, with a gross profit margin of 82.5% [3][12]. - The company's innovative drug sales reached CNY 7.8 billion, growing by 27% year-on-year, while generic drug revenue was CNY 9.8 billion, showing slight growth [4][13]. - The report highlights the strong growth drivers in oncology and surgery/analgesia segments, with oncology revenue at CNY 6.7 billion (+25% YoY) and surgery/analgesia revenue at CNY 3.1 billion (+20% YoY) [19]. Financial Performance - Revenue forecasts for 2025 and 2026 have been raised to CNY 33.4 billion and CNY 37.6 billion, respectively, due to expected growth in out-licensing revenue [17]. - Net profit attributable to parent shareholders is adjusted to CNY 4.8 billion and CNY 5.1 billion for FY25E and FY26E, respectively [17]. - The report indicates a projected diluted EPS of CNY 0.27 for 2025 and CNY 0.28 for 2026, with a gross profit margin expected to remain stable at 82.5% [10][17]. Clinical Pipeline and Growth Potential - The respiratory portfolio includes multiple candidates in clinical stages, with significant progress in PDE3/4 inhibitors for COPD and TSLP monoclonal antibodies for asthma [4][14]. - Six innovative products are expected to launch in 2025, including key products like TQB3616 (CDK2/4/6 inhibitor) and HER2 inhibitors [15][16]. - The report emphasizes the potential for out-licensing several innovative products in oncology and respiratory pipelines, which could enhance revenue streams [16].